19 June 2025 - NICE has published final evidence-based recommendations on the use of atezolizumab (Tecentriq) for the adjuvant treatment of adults with resected non-small-cell lung cancer.

Atezolizumab can be used, within its marketing authorisation, as an option for the adjuvant treatment of adults with non-small-cell lung cancee after complete resection and platinum-based chemotherapy when:

• There is a high risk of recurrence
• 50% or more of tumour cells express PD‑L1
• The cancer is not epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK) positive.

Atezolizumab can only be used if Roche provides it according to the commercial arrangement.

Read NICE technology appraisal guidance